For adults with diabetes and obesity, GLP-1 RAs are associated with a reduced risk for obesity-related cancer compared with DPP-4 inhibitors.

Obesity and cancer form a troubling link in the United States. Over 40% of adults are obese, and more than 70% are overweight.

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl ...

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

The fact is more and more younger people are being diagnosed with colon cancer. For one local woman, her cancer came when she least expected it.

About 40 percent of cancer cases are considered preventable. Try these lifestyle changes to stay healthy.

A recent study associated resistance training with a 52% lower breast cancer risk in young adults compared to those who never ...

Ms. McKay is a war and humanitarian-focused international correspondent and author of 'Only Cry for the Living: Memos from ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity.